Is ZGNX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,339 people get ZGNX articles and Market Currents by email alert.

Get email alerts on ZGNX »

HEADLINES:

Zogenix's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
Zogenix Reports First Quarter 2013 Financial Results

GlobeNewswire (May 9, 2013)
Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

GlobeNewswire (May 3, 2013)
Zogenix Poised For 40% Haircut As Zohydro Decision Approaches
PropThink • Thu, May 2 • 31 Comments
Zogenix Reports Positive Top-Line Results From Extended Relday(TM) Phase 1 Clinical Trial

GlobeNewswire (May 2, 2013)
Zohydro - Is There Enough Upside For Zogenix?
Bay Area Biotech • Tue, Apr 30 • 10 Comments
Alkermes Still Not Getting Full Credit For Its Pipeline
Stephen Simpson • Fri, Apr 5 • 1 Comment
Why Zohydro May Or May Not Be Approved
Abraham David • Thu, Apr 4 • 32 Comments
Zogenix and Battelle Extend DosePro Co-Marketing Partnership

GlobeNewswire (Mar 27, 2013)
Zogenix's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Fri, Mar 15 • 1 Comment
Zogenix Reports Fourth Quarter and Full Year 2012 Financial Results

GlobeNewswire (Mar 15, 2013)
Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2012 Financial Results

GlobeNewswire (Mar 7, 2013)
Titan As A Hedge For Zogenix
Natty Greene • Wed, Feb 27 • 12 Comments
Zogenix Provides Update on Zohydro(TM) ER Regulatory Review

GlobeNewswire (Feb 26, 2013)
5 Speculative Biotech Stocks With Catalysts Pending
Brian Nichols • Mon, Feb 25 • 8 Comments
Speculative Biotech Stocks That Could Bounce, Part 2
BuySellShort • Wed, Feb 13 • 5 Comments
BioLineRx: Upcoming Catalyst With Potential Multi Billion-Dollar Schizophrenia Drug
Scott Matusow • Tue, Jan 15 • 23 Comments
Upcoming FDA Approval Decision Dates For Q1 2013
David Zanoni • Sun, Jan 13 • 13 Comments
Is There Life For Zogenix After Zohydro?
C.R. Jackson • Thu, Jan 10 • 5 Comments
Zogenix Announces Preliminary Fourth Quarter 2012 Gross Product Sales

GlobeNewswire (Jan 7, 2013)

To learn more about Seeking Alpha Pro, click here.

Zogenix Poised For 40% Haircut As Zohydro Decision Approaches
PropThink • Thu, May 2 • 31 Comments
Zohydro - Is There Enough Upside For Zogenix?
Bay Area Biotech • Tue, Apr 30 • 10 Comments
Why Zohydro May Or May Not Be Approved
Abraham David • Thu, Apr 4 • 32 Comments
Is There Life For Zogenix After Zohydro?
C.R. Jackson • Thu, Jan 10 • 5 Comments
Is Zogenix A Buy After FDA Panel Says 'No' To Zohydro?
C.R. Jackson • Fri, Dec 14, 2012 • 15 Comments
FDA Advisory Meeting Leaves Zogenix Stock In Tatters
Brian L. Wilson • Fri, Dec 14, 2012
Zogenix: Upcoming Catalysts Should Provide Upside
Scott Matusow • Tue, Oct 2, 2012 • 26 Comments
Zogenix's Zohydro ER: A Safer Opioid For Chronic Pain
Ankit Desai • Mon, Oct 1, 2012 • 26 Comments
A Look At Zogenix - Zohydro Drug Information And Analysis
Bob's Stocks • Mon, Sep 17, 2012 • 25 Comments
Zogenix: Why This Hated Biotech Deserves Love
Deep Value Investor • Tue, Apr 17, 2012 • 21 Comments
Zogenix: Smart Biotech Buy Before Earnings
Natty Greene • Mon, Mar 5, 2012 • 47 Comments
Insiders And Institutions Aggressively Buying Zogenix
Natty Greene • Mon, Feb 6, 2012 • 7 Comments
Top Biotech Pick For 2012: Zogenix
Natty Greene • Tue, Jan 3, 2012 • 6 Comments
Zogenix IPO: Invest in Curing Migranes
SA Editor Mohit Manghnani • Fri, Dec 3, 2010 • 2 Comments

Alkermes Still Not Getting Full Credit For Its Pipeline
Stephen Simpson • Fri, Apr 5 • 1 Comment
Titan As A Hedge For Zogenix
Natty Greene • Wed, Feb 27 • 12 Comments
5 Speculative Biotech Stocks With Catalysts Pending
Brian Nichols • Mon, Feb 25 • 8 Comments
Speculative Biotech Stocks That Could Bounce, Part 2
BuySellShort • Wed, Feb 13 • 5 Comments
BioLineRx: Upcoming Catalyst With Potential Multi Billion-Dollar Schizophrenia Drug
Scott Matusow • Tue, Jan 15 • 23 Comments
Upcoming FDA Approval Decision Dates For Q1 2013
David Zanoni • Sun, Jan 13 • 13 Comments
2 Biotech Companies Making Considerable Strides When It Comes To Pain Management
Matt Schilling • Thu, Jan 3 • 6 Comments
3 Biotech Stocks To Consider In The Wake Of Recent Developments
Matt Schilling • Wed, Dec 19, 2012 • 2 Comments
3 Healthcare Stocks With Recent Intensive Insider Buying
Markus Aarnio • Wed, Dec 19, 2012 • 9 Comments
Recent Developments Plus Short Interest Could Push Star Scientific's Rally Even Higher
Scott Matusow • Tue, Dec 11, 2012 • 22 Comments
Biotech Weekly Recap: The Market Holds While Biotech Crumbles
Brian L. Wilson • Sun, Dec 9, 2012 • 6 Comments
Important Catalysts For 3 Biotech Companies
LifeSci Advisors • Fri, Dec 7, 2012 • 3 Comments
3 Small-Cap Biopharmas With Trade Catalysts And Speculation Investment Potential
Scott Matusow • Tue, Dec 4, 2012 • 21 Comments
2 Speculative Biotech Plays That Have Potential
Matt Schilling • Fri, Nov 9, 2012 • 2 Comments
3 Best Biotech Stocks For This Week (Part V)
Jorge Aura • Mon, Oct 8, 2012 • 2 Comments
3 Best Biotech Stocks For This Week (Part IV)
Jorge Aura • Wed, Oct 3, 2012 • 4 Comments
Durect Corporation - A Unique & Undervalued Biopharma Development Company
Kyle Walker • Thu, Aug 30, 2012 • 9 Comments
5 Pharmaceutical Companies With PDUFA Dates In Q1 2013
Markus Aarnio • Thu, Aug 9, 2012 • 11 Comments
Why Early Tuesday's Biotech Edge Is Bullish
James Stocklasar Thomas Jr. • Tue, Jul 17, 2012 • 17 Comments
Top Micro Cap Biotech Stocks Being Accumulated By Legendary Fund Managers
GuruFundPicks • Tue, Apr 17, 2012 • 12 Comments

Zogenix's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
Zogenix's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Fri, Mar 15 • 1 Comment
Zogenix's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Fri, Nov 9, 2012
Zogenix's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Wed, Aug 8, 2012

Zogenix Reports First Quarter 2013 Financial Results

GlobeNewswire (May 9, 2013)
Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

GlobeNewswire (May 3, 2013)
Zogenix Reports Positive Top-Line Results From Extended Relday(TM) Phase 1 Clinical Trial

GlobeNewswire (May 2, 2013)
Zogenix and Battelle Extend DosePro Co-Marketing Partnership

GlobeNewswire (Mar 27, 2013)
Zogenix Reports Fourth Quarter and Full Year 2012 Financial Results

GlobeNewswire (Mar 15, 2013)
Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2012 Financial Results

GlobeNewswire (Mar 7, 2013)
Zogenix Provides Update on Zohydro(TM) ER Regulatory Review

GlobeNewswire (Feb 26, 2013)
Zogenix Announces Preliminary Fourth Quarter 2012 Gross Product Sales

GlobeNewswire (Jan 7, 2013)
Zogenix Reports Positive Results From Relday(TM) Phase 1 Clinical Trial

GlobeNewswire (Jan 3, 2013)
Mark Hulbert: Small is beautiful, tiny is even better

at MarketWatch.com (Jan 2, 2013)
Movers & Shakers: Monday’s big movers: Mr. Dimon goes to Washington

at MarketWatch.com (Dec 10, 2012)
Zogenix Provides Update on FDA Advisory Committee Meeting for Zohydro(TM) ER for Management of Chronic Pain

GlobeNewswire (Dec 7, 2012)
Trading of Zogenix Common Stock Halted

GlobeNewswire (Dec 7, 2012)
Zogenix Appoints New Chief Commercial Officer

GlobeNewswire (Nov 26, 2012)
Zogenix to Present at the 24th Annual Piper Jaffray Healthcare Conference

GlobeNewswire (Nov 15, 2012)
Preliminary Findings From Rheumatoid Arthritis Patient Survey Reveal Strong Interest in Needle-Free Self-Injection

GlobeNewswire (Nov 13, 2012)
Zogenix Reports Third Quarter 2012 Financial Results

GlobeNewswire (Nov 8, 2012)
Zogenix Announces FDA Advisory Committee Review of Zohydro(TM) ER for the Management of Chronic Pain

GlobeNewswire (Nov 8, 2012)
Zogenix Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results

GlobeNewswire (Oct 25, 2012)
Zogenix to Present New Case Study Highlighting Successful Repositioning of Injectable Sumatriptan for Migraine With a Novel Needle-Free Delivery Technology

GlobeNewswire (Oct 23, 2012)

ZGNX vs. ETF Alternatives

Company Description

Currently, there's no company description for ZGNX.

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 10, 3:36 PM Shares of Endo Health (ENDP -3.6%) trade lower following a brief halt after the FDA denies its petition to block generic versions of its Opana ER. ZGNX +2.1%, IPXL +8.4%. Comment! [Healthcare, On the Move]
Thursday, May 9, 7:50 PM More on Zogenix (ZGNX): Q1 misses on all counts. Net product revenues declined Y/Y, driven by the increase to the return reserve and the resetting of health insurance co-pays and co-insurance at the beginning of the year, which slowed patient volumes to a greater degree than in previous years. Product gross margin was 40%, compared to 49% in Q112, due to higher cost per unit and a decrease in the net selling price. Shares -2.4% AH. Comment! [Healthcare, Earnings, On the Move]
Thursday, May 9, 4:11 PM Zogenix (ZGNX): Q1 EPS loss of -$0.21 misses by $0.07. Revenue of $7M (-24% Y/Y) misses by $2.28M. (PR). Conference Call at 4:30 ET: (Webcast). Comment! [Breaking News, Healthcare, Earnings]
Thursday, May 9, 12:10 AM Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX Comment! [Earnings]
Wednesday, May 8, 5:35 PM Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX Comment! [Earnings]
Wednesday, April 17, 9:12 AM Premarket gainers: VRML +29%. ACUR +26%. OCZ +18%. CUR +9%. ALKS +9%. ABMD +9%. ASML +6%.
Losers: EOPN -29%. INWK -25%. CXW -15%. MHR -12%. ZGNX -11%. TXT -9%. CRUS -7%. VRNG -6%. 1 Comment [On the Move]
Wednesday, March 27, 2:14 PM Zogenix (ZGNX -0.8%) and Battelle, the world's largest independent research and development organization, say they've extended a co-marketing partnership for the DosePro needle-free drug delivery system through March, 2014. The partnership is focused on advancing the out-licensing opportunities for the system, with a focus on co-marketing the technology to potential biopharmaceutical and government clients. Comment! [Healthcare, On the Move]
Friday, March 15, 12:20 PM Drug developer Zogenix (ZGNX +4.3%) moves up today after posting a narrower-than-expected Q4 loss. Total sales came in at $9.5M, up 12% Y/Y, and consisted solely of net product revenue. Cost of sales was $6M, +20% over the prior-year period. Gross margin soared to 37% compared to 9% in Q411, driven largely by an increase in average net selling prices. Comment! [Healthcare, Earnings, On the Move]
Friday, March 15, 9:15 AM Premarket gainers: CNP +10%. SNE +8%. ZGNX +6%. OGE +6%. PANL +5%.
Losers: GLDD -22%. ULTA -14%. STEC -13%. ARO -7%. VHC -6%. CG -6%. KKD -5%. Comment! [On the Move]
Friday, March 15, 7:39 AM Zogenix (ZGNX): Q4 EPS of -$0.16 beats by $0.01. Revenue of $9.5M misses by $0.37M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, March 15, 12:05 AM Notable earnings before Friday’s open: CRME, PGNX, ZGNX Comment! [Earnings]
Thursday, March 14, 5:30 PM Notable earnings before Friday’s open: CRME, PGNX, ZGNX Comment! [Earnings]
Thursday, February 28, 12:53 PM Midday top 10 gainers: RNIN +65%. IFMI +60%. HGSH +23%. ANIK +18%. FSGI +17%. PANL +16%. LTBR +16%. ZGNX +15%. FARO +14%. ATSG +13%.
Midday top 10 losers: PKT -29%. BSFT -28%. IMH -20%. GRPN -19%. JCP -15%. FREE -12%. AMBO -12%. GVA -11%. TEO -11%. DVR -11%. Comment! [On the Move]
Thursday, February 28, 9:10 AM Premarket gainers: MNOV +11%. BDBD +10%. RTK +8%. ZGNX +7%. NEO +7%. NBG +6%.
Losers: GRPN -29%. BSFT -23%. JCP -16%. PKT -15%. MTG -14%. MCP -8%. CWH -7%. 1 Comment [On the Move]
Wednesday, February 27, 12:55 PM Midday top 10 gainers: ZGNX +39%. UNXL +24%. FSGI +21%. GWRE +18%. ELMD +16%. PDCE +14%. OPTR +13%. DLTR +12%. END +11%. SHI +11%.
Midday top 10 losers: AH -26%. CBB -23%. AMBO -22%. RNIN -21%. CBMX -19%. XWES -19%. FSLR -16%. CMGE -15%. CRMB -13%. PRPH -12%. Comment! [On the Move]
Wednesday, February 27, 10:49 AM Zogenix (ZGNX +44%) continues to surge higher this morning on the news of the FDA decision to push back its PDUFA date for Zohydro. Analysts see the delay as a potential positive, as it's likely to be short-lived and the odds for eventual approval are still high. Wells Fargo's Michael Tong sees just 20% downside on a negative FDA decision but potentially 100%+ upside for the stock if given the green light. Comment! [Healthcare, On the Move]

nsahbti
$ZGNX Tic Toc Tic Toc... Approval date coming up
Apr 22, 10:15 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

nsahbti
$ZGNX any estimate of when approval?
Mar 20, 11:23 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

nsahbti
$ZGNX lots of short covers in anticipation of approval?
Feb 28, 9:58 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

tradesurf
are the $ZGNX notes going to be released at 12am east coast time?
12/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
From yesterday: $ZGNX chart and $SRPT: Did I get it right? find out at http://bit.ly/Qss4GL
10/3/12
Reply (8)

• !Report Abuse
View all 8 replies
Scott Matusow: Thanks Guys! and good to hear Droney, glad I can help offer ideas to people. Thank Seeking Alpha as well for allowing so many diverse ideas.
10/3/12
• !Report Abuse
tradesurf: do you know if the $ZGNX notes news will be released at 12am eastern time or west coast time?
12/5/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Calling the ball Viper = $3.03 for $ZGNX by days end = #FAIL
10/2/12
Reply (2)

• !Report Abuse
View all 2 replies
jakerogers77: Close, though!
10/3/12
• !Report Abuse
Scott Matusow: on tuesday I missed, for today I was dead on @ http://bit.ly/OE1LR7
10/3/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Calling the ball Viper = $3.03 for $ZGNX by days end = #FAIL
10/2/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
Calling the ball Viper = $3.03 for $ZGNX by days end.
10/2/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
I am long now on $ZGNX playing for a move to $3.50 which I think is obviously doable.
10/1/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

DAG1996
ZGNX on a tear today. Did some news come out?
3/5/12
Reply (11)

• !Report Abuse
View all 11 replies
DAG1996: yes. i factor some losses into my biotech plays... as long as i make more than i lose i'm happy. lol
3/5/12
• !Report Abuse
John Rayhall: Lol yes me too that's the name of the game after all :)
3/5/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Scott Matusow
From yesterday: $ZGNX chart and $SRPT: Did I get it right? find out at http://bit.ly/Qss4GL
10/3/12
Reply (8)

• !Report Abuse
View all 8 replies
Scott Matusow: Thanks Guys! and good to hear Droney, glad I can help offer ideas to people. Thank Seeking Alpha as well for allowing so many diverse ideas.
10/3/12
• !Report Abuse
tradesurf: do you know if the $ZGNX notes news will be released at 12am eastern time or west coast time?
12/5/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Calling the ball Viper = $3.03 for $ZGNX by days end = #FAIL
10/2/12
Reply (2)

• !Report Abuse
View all 2 replies
jakerogers77: Close, though!
10/3/12
• !Report Abuse
Scott Matusow: on tuesday I missed, for today I was dead on @ http://bit.ly/OE1LR7
10/3/12
• !Report Abuse
Add a reply...

140 characters

DAG1996
ZGNX on a tear today. Did some news come out?
3/5/12
Reply (11)

• !Report Abuse
View all 11 replies
DAG1996: yes. i factor some losses into my biotech plays... as long as i make more than i lose i'm happy. lol
3/5/12
• !Report Abuse
John Rayhall: Lol yes me too that's the name of the game after all :)
3/5/12
• !Report Abuse
Add a reply...

140 characters

Husky Financial
CRR and KIT two of my stock screen highlights from tonight. Also added TRU and ZGNX to the watch list as well.I wrote an entire blog on this
2/15/12
Reply (9)

• !Report Abuse
View all 9 replies
Husky Financial: 164m mkt cap 70m in cash on the books..87% inst. owned.. dunno on an entry.. maybe $2.00-$2.25? got some nice stuff in the pipeline
2/15/12
• !Report Abuse
DAG1996: ok i misunderstood. yes, good inst. onws & decent cash. bios burn cash very fast though. some political issues too. i'll probably open small
2/16/12
• !Report Abuse
Add a reply...

140 characters

ZGNX Zogenix, Inc.

ZGNX

Zogenix, Inc.